Screener
CONMED CNMD G&A
G&A at other companies
Other financials
Where this comes from
Reported directly by CONMED in its filing.
Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.
The source filing: CONMED’s 10-Q, filed July 29, 2026.
- Filed
- Jul 29, 2026, 4:13 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000816956-26-000102
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Salesforce and commission expense | 59,150 | 58,923 | 117,367 | 116,355 |
| Marketing expense | 19,178 | 16,992 | 37,292 | 32,867 |
| Distribution expense | 14,168 | 13,152 | 27,423 | 25,185 |
| General and administrative expense | 31,143 | 33,016 | 63,537 | 65,670 |
| Stock-based compensation expense | 5,230 | 4,903 | 10,732 | 18,766 |
| Amortization expense | 7,237 | 7,192 | 14,498 | 14,364 |
| Non-cash adjustments to fair value of contingent consideration liability | (113) | (1,799) | 610 | 2,163 |
| Research and development expense(b) | 15,500 | 14,138 | 31,833 | 27,084 |
Item 1. Financial Statements (unaudited)
FAQ
- What is CONMED's G&A?
- CONMED (CNMD) reported G&A of $31.14M in Q2 2026.
- How has CONMED's G&A changed year-over-year?
- CONMED's G&A decreased by 5.7% year-over-year, from $33.02M to $31.14M.
- What is the long-term trend for CONMED's G&A?
- Over 3 years (2022 to 2025), CONMED's G&A has grown at a 11.1% compound annual growth rate (CAGR), from $96.11M to $131.97M.
- What does G&A mean?
- Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.
Ask your AI about CONMED's g&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude